Navigation Links
Arena Pharmaceuticals to Present at the Seventh Annual JMP Securities Healthcare Conference
Date:7/9/2012

SAN DIEGO, July 9, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present at the Seventh Annual JMP Securities Healthcare Conference on Thursday, July 12, 2012, at 9 a.m. Eastern Time (6 a.m. Pacific Time) at The Peninsula New York Hotel in New York City. Craig M. Audet, Arena's Senior Vice President, Operations and Head of Global Regulatory Affairs, is scheduled to provide a corporate overview.

A live audio webcast of the presentation will be available under the investor relations section of Arena's website at www.arenapharm.com. A replay of the presentation will be available for 30 days following the event. Please connect to Arena's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

About Arena PharmaceuticalsArena Pharmaceuticals, Inc., is a biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors, an important class of validated drug targets, in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. For more information about Arena Pharmaceuticals, please visit www.arenapharm.com.

Arena Pharmaceuticals® and Arena® are registered service marks of Arena Pharmaceuticals, Inc.

Forward Looking StatementsCertain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's focus, goals, strategy, research and development programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: the timing and outcome of DEA, EMA and other regulatory review is uncertain; limitations on the indicated uses, distribution, marketing and other limitations on BELVIQ or, if approved, any of Arena's other drug candidates; risks related to commercializing drugs, including regulatory, manufacturing and supply issues and the pace of market acceptance; cash and revenues generated from BELVIQ, including timing and impact of competition; government and commercial reimbursement and pricing decisions; risks related to relying on collaborative agreements; the timing and receipt of payments and fees, if any, from collaborators; unexpected or unfavorable new data; nonclinical and clinical data is voluminous and detailed, and regulatory agencies may interpret or weigh the importance of data differently and reach different conclusions than Arena or others, request additional information, have additional recommendations or change their guidance or requirements before or after approval; data and other information related to any of Arena's research and development programs may not meet safety, efficacy or other regulatory requirements or otherwise be sufficient for regulatory review, approval or continued marketing; Arena's ability to obtain and defend patents; the timing, success and cost of Arena's research and development programs; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner expected or at all; having adequate funds; and satisfactory resolution of litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.Contacts: Arena Pharmaceuticals, Inc. 858.453.7200Investor Contact: Russo Partners, LLC

Media Contact: Russo Partners, LLCCindy McGee, Vice President

David Schull, President cindy.mcgee@russopartnersllc.com

david.schull@russopartnersllc.com 619.213.6995

858.717.2310


'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Arena Pharmaceuticals Promotes Craig M. Audet to Executive Officer as Senior Vice President, Operations and Head of Global Regulatory Affairs
2. Aperture Health, Inc., Targeting the Strong Growth in the Long Term Disease Management arena
3. Arena Pharmaceuticals Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
4. Arena Pharmaceuticals Announces Proposed Public Offering of Common Stock
5. Arena Pharmaceuticals Announces First Quarter 2012 Financial Results and Recent Developments
6. SOCMAs Bulk Pharmaceuticals Task Force Hails Signing of FDA Reform Act into Law
7. India Pharmaceuticals and Healthcare Report Q3 2012
8. Savient Pharmaceuticals Announces CEO Appointment and Reorganization Plan to Drive Long-Term Growth
9. ADVENTRX Pharmaceuticals To Present At The OneMedForum New York 2012 Emerging Company Finance Conference On July 12
10. Onyx Pharmaceuticals Names John E. Osborn Senior Vice President, Global Corporate Affairs
11. Inovio Pharmaceuticals to Present at JMP Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... 4, 2016   Bernstein Liebhard LLP today announced ... United States District Court for the District of ... consisting of all persons or entities who purchased common shares ... INSY ) from March 3, 2015 through January 25, 2016 ... its officers with violations of the Securities Exchange Act of ...
(Date:2/4/2016)... LONDON , Feb. 4, 2016 ... Summary Global Markets Direct,s, ,Wegener Polyangiitis - ... the Wegener Polyangiitis,s therapeutic pipeline. This report ... Wegener Polyangiitis, complete with comparative analysis at various ... action (MoA), route of administration (RoA) and molecule ...
(Date:2/4/2016)... Summary Breast cancer, a malignant neoplasm, is the ... in women worldwide, accounting for 16% of all female ... women diagnosed with breast cancer has increased over the ... declined due to earlier diagnosis and better treatment options. ... past four decades, especially with increasing usage of targeted ...
Breaking Medicine Technology:
(Date:2/5/2016)... Lake City, UT (PRWEB) , ... February 05, 2016 , ... ... Activz Whole-Food Nutrition , announced that the much-anticipated feature with author Jahnavi Foster, specialist ... Cool Humans Amateur TV Network. , Each week, on his weekly Whole-Food Warrior TV ...
(Date:2/5/2016)... , ... February 05, 2016 , ... ... the addition of micro-needling services in their Napa Valley office. The technique utilizes ... Plastic Surgery Associates, Dr. Canales and Dr. Furnas, are part of only a ...
(Date:2/5/2016)... ... 05, 2016 , ... The Lymphoma Research Foundation (LRF) – ... serving the lymphoma community through a comprehensive series of education programs, outreach initiatives ... Tasting Event at the La Gorce Country Club in Miami Beach on March ...
(Date:2/5/2016)... York, New York (PRWEB) , ... February 05, 2016 , ... ... gym use and find themselves having to wait longer to access the treadmills. It’s ... their New Year’s resolutions to lose weight and get in shape by joining gyms, ...
(Date:2/5/2016)... New York, New York (PRWEB) , ... February 05, 2016 , ... ... (APDA) announced the election of Patrick McDermott as Chairman of the National Board of ... welcome Pat as Chairman of the Board,” stated Leslie A. Chambers , APDA ...
Breaking Medicine News(10 mins):